Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day Results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) Study by Jeong, Young-Hoon et al.
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bjectives This study sought to determine the impact of gene polymorphisms on platelet reactivity
PR) after clopidogrel 150 mg/day in patients treated with percutaneous coronary intervention (PCI).
ackground Although high maintenance-dose (MD) clopidogrel reduces PR, it is unknown whether gene
olymorphisms are related with the risk of high post-treatment PR (HPPR) after high-MD clopidogrel.
ethods We included mostly patients receiving high-MD clopidogrel after PCI from previously reg-
stered Gyeongsang National University Hospital data. A total of 126 PCI-treated patients receiving
igh-MD clopidogrel were enrolled. Platelet reactivity was assessed with conventional aggregometry
nd VerifyNow (Accumetrics Inc., San Diego, California) after receiving clopidogrel 150 mg/day for at
east 1 month. CYP3A5, CYP2C19, and ABCB1 genotyping was performed. We deﬁned HPPR as 5 mol/l
denosine diphosphate (ADP)–induced maximal PR (PRmax) 50%.
esults CYP3A5 and ABCB1 polymorphisms did not inﬂuence PR. Carriers of CYP2C19 variant (*2 or *3)
n  80) had signiﬁcantly higher 5 and 20 mol/l ADP-induced PRmax than did noncarriers (n  46)
40.7  16.8% vs. 30.3  12.6%, p  0.001; 54.2  16.2% vs. 40.5  15.8%, p  0.001, respectively).
ate PR and VerifyNow results indicated consistently greater measures in carriers versus noncarriers of
YP2C19 variant. All platelet measures proportionally increased according to the number of CYP2C19 vari-
nt alleles. Twenty-seven (21.4%) patients met the criteria for HPPR. Prevalence of HPPR was 8.7%, 21.7%,
nd 50.0% in carriers of 0, 1, and 2 CYP2C19 variant alleles, respectively (p  0.001). By multivariate anal-
sis, carriage of CYP2C19 variant was a signiﬁcant predictor of HPPR (odds ratio: 5.525, 95% conﬁdence
nterval: 1.333 to 23.256, p  0.018).
onclusions Among PCI-treated patients receiving high-MD clopidogrel, carriage of CYP2C19 variant
elates to increased PR and predicts risk of HPPR. (Adjunctive Cilostazol Versus High Maintenance-
ose ClopidogrEL in Acute Myocardial Infarction [AMI] Patients According to CYP2C19 Polymorphism
ACCELAMI2C19]; NCT00915733; and Comparison of Platelet Inhibition With Adjunctive Cilostazol
ersus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19)
olymorphism [ACCEL2C19]; NCT00891670). (J Am Coll Cardiol Intv 2010;3:731–41) © 2010 by the
merican College of Cardiology Foundation
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732ecause platelets play a critical role in atherothrombosis
fter acute coronary syndrome (ACS) or percutaneous
oronary intervention (PCI) (1,2), adequate platelet inhibi-
ion is important to minimize the risk of recurrent ischemic
ardiovascular events. Although a combination of aspirin and
lopidogrel is the current standard antiplatelet therapy follow-
ng ACS and PCI (3–5), antiplatelet response to clopidogrel is
ighly variable (6,7), and a higher level of on-treatment platelet
eactivity (PR) has been associated with an increased risk of
ardiovascular events (8–10). Therefore, intensified antiplatelet
egimens have been introduced to achieve consistent and
otent inhibition of adenosine diphosphate (ADP)–induced
latelet aggregation (11–13).
A higher dose of clopidogrel
also can obtain a more rapid
and greater degree of platelet
inhibition (14,15), and the
CURRENT/OASIS 7 (Clopi-
dogrel Optimal Loading Dose
Usage to Reduce Recurrent
Events/Optimal Antiplatelet
Strategy for Interventions) study
(13) showed that a double dose of
clopidogrel for 7 days in PCI-
treated patients with ACS can
reduce the risk of major adverse
cardiovascular events by 15%. Al-
though various factors including
patient characteristics and drug-
drug interactions can affect anti-
platelet response to clopidogrel,
gene polymorphisms underlie en-
hanced PR and higher rates of
ischemic events to a great extent
(16,17). Because clopidogrel, re-
gardless of dose, is converted to its
active metabolite through the
same metabolic pathway, it is un-
certain whether gene polymor-
phisms are associated with the risk
of high post-treatment PR
HPPR) in patients on a higher dose of clopidogrel (18).
The purpose of this study, therefore, was to determine the
mpact of gene polymorphisms on residual PR with a high
ose of clopidogrel. We assessed the risk of HPPR and the
ssociation of gene polymorphisms with HPPR after a high
aintenance-dose (MD) clopidogrel of 150 mg/day in PCI-
reated patients.
ethods
atient population and study design. A total of 126 PCI-
reated patients with available deoxyribonucleic acid (DNA)
bbreviations
nd Acronyms
CS  acute coronary
yndrome
DP  adenosine
iphosphate
MI  body mass index
KD  chronic kidney
isease
YP  the hepatic
ytochrome P450
NA  deoxyribonucleic acid
PPR  high post-treatment
latelet reactivity
D  maintenance-dose
CI  percutaneous
oronary intervention
CR  polymerase chain
eaction
R  platelet reactivity
Rlate  late platelet
ggregation at 5 min
Rmax  maximal platelet
ggregation
RU  P2Y12 reaction unit
M  reduced metabolizerenotyping could be enrolled to the ACCEL-DOUBLEAccelerated Platelet Inhibition by a Double Dose of
lopidogrel According to Gene Polymorphism) study
Fig. 1). Patients were recruited at the Department of
ardiology of the Gyeongsang National University Hospi-
al between January 2008 and June 2009. One-hundred and six
atients were collected from a registry of the ACCEL (Ad-
unctive Cilostazol Versus High-MD Clopidogrel) studies
19,20), which were performed to compare the degree of
latelet inhibition by adjunctive cilostazol versus high-MD
lopidogrel in patients within a specific subset: HPPR, diabe-
es, drug-eluting stent implantation for complex lesions, and
cute myocardial infarction. The high-MD group received a
igh-MD clopidogrel of 150 mg/day for 1 month. A minority
n 20, 15.9%) of patients received high-MD clopidogrel for
ver 1 month after PCI at the attending physician’s discretion.
atient compliance to antiplatelet therapy was assessed by
nterview and tablet counting at the follow-up visit. Because
revious definitions of clopidogrel response using the difference
etween pre- and post-treatment PR overestimate ischemic
isk (7), we assessed the post-treatment threshold of PR.
ecause pharmacokinetic and pharmacodynamic responses
ay vary profoundly during the initial days or weeks after
ntiplatelet therapy (15), PR was assessed during the mainte-
ance phase of high-MD clopidogrel in addition to aspirin 200
g/day after PCI (1 month).
Patients were eligible for enrollment if they were 18
ears of age and had been treated with PCI for symptomatic
oronary artery disease. Exclusion criteria were known
llergies to antiplatelet therapy, left ventricular ejection
raction 30%, active bleeding and bleeding diatheses, oral
Figure 1. Flow Diagram of the ACCEL-DOUBLE Study
Flow diagram of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a
Double Dose of Clopidogrel According to Gene Polymorphism) study.
ABCB1  P-glycoprotein gene; ACCEL  Adjunctive Cilostazol Versus High
Maintenance-Dose Clopidogrel; CYP  the hepatic cytochrome P450; PCI 
percutaneous coronary intervention.
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733nticoagulation therapy with Coumadin, a leukocyte count
3,000/mm3 and/or a platelet count 100,000/mm3, an
spartate aminotransferase level or an alanine aminotrans-
erase level 3 times the upper normal limit, serum creat-
nine level 2.5 mg/dl, stroke within 3 months, noncardiac
isease with a life expectancy 1 year and inability to
eceive the regimen. The study protocol was approved by
he Institutional Ethics Committee of Gyeongsang Na-
ional University Hospital, Korea, and the patients provided
ritten informed consent to participate in this study.
latelet function assays. Within 2 to 4 h after the last intake
f regimen, blood samples were collected using the double-
yringe technique, and the first 2 to 4 ml of blood was
iscarded to avoid the bias of spontaneous platelet activa-
ion. Platelet reactivity was simultaneously measured 1 h
fter venipuncture by light transmittance aggregometry and
he VerifyNow P2Y12 assay (Ultegra rapid platelet function
ssay, Accumetrics Inc., San Diego, California). Correlation
etween 2 assays at our laboratory has been reported (21).
Platelet aggregation was assessed by light transmittance
ggregometry according to standard protocol (15,19,20).
lood samples were drawn into Vacutainer tubes containing
.5 ml of 3.2% sodium citrate (Becton-Dickinson, San Jose,
alifornia) and processed within 60 min. Platelet-rich plasma
as obtained as a supernatant fluid after centrifuging the blood
t 120 g for 10 min. The remaining blood was further
entrifuged at 1,200 g for 10 min to prepare platelet-poor
lasma. Examined sample was adjusted to platelet counts of
50,000/mm3. Platelet aggregation was assessed at 37°C using
n AggRAM aggregometer (Helena Laboratories Corpora-
ion, Beaumont, Texas). Platelet measures were performed
fter the addition of 5 and 20 mol/l ADP, and the curves
ere recorded for 10 min. Platelet reactivity was measured at
he peak (maximal PR [PRmax]) and at 5 min (late PR [PRlate])
y laboratory personnel blinded to the study protocol.
The VerifyNow P2Y12 assay is a whole-blood, point-of-
are system that has been developed to assess responsiveness to
2Y12 antagonists (22). Blood was drawn into a Greiner
io-One 3.2% citrate Vacuette tube (Greiner Bio-One,
remsmünster, Austria). The assay device consists of 2 whole-
lood assay channels. One contains fibrinogen-coated polysty-
ene beads, 20 mol/l ADP, and 22 nmol/l prostaglandin E1.
he other separate channel contains fibrinogen-coated poly-
tyrene beads and isothrombin receptor activating protein.
latelet aggregation by the isothrombin receptor activating
rotein (BASE) can occur independently of P2Y12 receptors.
he results are reported in P2Y12 reaction unit (PRU), BASE
nd % inhibition. The % inhibition is calculated as: ([BASE-
RU]/BASE)  100.
enotyping and metabolic phenotype. We performed geno-
yping of the CYP3A5*3, CYP2C19*2 and *3, and ABCB1
ariants according to previous studies (16,17,23–25). The
ase numbering and allele definitions follow the nomencla-
ure of the Human CYP Allele Nomenclature Committee. aenomic DNA was extracted from leukocytes of whole-
lood specimens with a commercially available kit (QIAamp
NA Blood Mini Kit, Qiagen, Hilden, Germany).
Because the allelic frequencies of the CYP2C19*4 to *6 are
xtremely rare in East Asians (26,27), genotyping for
YP2C19*2 (rs4244285, c.681GA) and CYP2C19*3
rs4986893, c.636GA) were investigated using the ABI
NaPshot (Applied Biosystems, Foster City, California) reac-
ion (Fig. 2). Polymerase chain reaction (PCR) was carried out
y using the same primers as previously described (24). The
CR product was processed as per the ABI SNaPshot proto-
ol, using primers designed for fluorescent dideoxy nucleotide
ermination. Single nucleotide polymorphisms analysis was
arried out on the ABI 3100 genetic analyzer (Applied Bio-
ystems, Foster City, California). Genotyping for the
YP3A5*3 (rs776746, g.6986AG) and ABCB1 (rs1045642,
.3435CT) was performed with the use of an allelic discrim-
nation assay based on the TaqMan method (Applied Biosys-
ems) and ABI PRISM 7900HT Sequence Detection System
SDS) (Applied Biosystems). The PCR amplification protocol
or the TaqMan assays included denaturation at 95°C for 10
in, followed by 40 cycles at 92°C for 15 s, 60°C for 1 min,
nd 72°C for 45 sec, followed by elongation at 72°C for 5 min.
he TaqMan assays were then read on a 7900HT Fast
eal-Time PCR System and alleles were called using SDS
oftware.
In the case of the CYP2C19 and ABCB1, carriers of any
oss-of-function allele were categorized as reduced metabo-
izers (RMs). In terms of the CYP3A5, carriers of 2 mutant
lleles were defined as RMs (25).
nd points and deﬁnition. Primary end point was PRmax
ccording to DNA genotypes. Secondary end points were:
) PRlate; 2) PRU; 3) percentage of inhibition; and 4) the rate
nd predictors of HPPR according to DNA genotypes. On
hronic clopidogrel therapy, patients with 5 mol/l ADP-
nduced PRmax 50%, or diabetic subjects with 20 mol/l
DP-induced PRmax 62% have shown a higher risk of
ong-term adverse cardiovascular events (28,29). Because we
emonstrated that these cutoffs were similar (21), HPPR was
efined as 5 mol/l ADP-induced PRmax 50%.
ample size calculation and statistical analysis. We assumed
25% difference in 5 mol/l ADP-induced PRmax between
arriers versus noncarriers of the CYP2C19 variant on a
igh-MD clopidogrel. Based on our previous study (24),
revalence of the CYP2C19 variant carriage was considered as
pproximately 60% in the East Asian population. Thus, it was
stimated that a total of 95 patients (57 carriers and 38
oncarriers of the CYP2C19 variant allele) would be required
o provide a power of 90% to detect a statistically significant
ifference with a 2-sided alpha-level of 0.05.
Continuous variables, presented as mean  SD, were
ompared using the Student unpaired t test or Mann-Whitney
test. Categorical variables, presented as numbers or percent-ges, were compared using chi-square tests or Fisher exact tests
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734s appropriate. Platelet measures and baseline characteristics
ccording to DNA genotyping were analyzed using a 1-way
nalysis of variance test. After demonstration of significant
ifferences among variables by analysis of variance, post hoc
omparisons among the groups were made with the Student-
ewman-Keuls procedure for multiple comparisons. The ge-
otypic frequencies were compared by chi-square analyses, and
eparture from Hardy-Weinberg equilibrium was tested. To
etermine predictors of HPPR, a logistic regression analysis
Figure 2. Genotyping Using ABI SNaPshot Method
CYP2C19*2 (rs4244285, c.681GA) (A) and CYP2C19*3 (rs4986893, c.636GA) (B) gas performed using known variables, and odds ratio (OR) and f5% confidence interval (CI) were also calculated. A value of
 0.05 was considered to indicate a significant difference. All
he statistical analyses were performed using SPSS version 13.0
SPSS Inc., Chicago, Illinois).
esults
atient characteristics and DNA genotypes. All patients
howed complete compliance with a high-MD clopidogrel
ping using ABI SNaPshot method (Applied Biosystems, Foster City, California).or at least 30 days. No major cardiovascular and bleeding
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735vents were observed in any patient during the follow-up.
ne patient in the noncarrier group suffered from TIMI
Thrombolysis In Myocardial Infarction) minor bleeding
uring the follow-up period, which was related with an
ntry-site hematoma. Baseline characteristics of the patients
re demonstrated in Table 1. Patients comprised relatively
Table 1. Baseline Characteristics According to Carria
Variables
Total
(n  126)
Nonca
(n 
Age, yrs 61.6 11.0 61.8
Male sex 85 (67.5) 29 (63
Body mass index, kg/m2 24.8 2.9 24.8
Index clinical presentation
Stable angina 28 (22.2) 6 (13
Unstable angina 34 (27.0) 15 (32
NSTEMI 28 (22.2) 9 (19
STEMI 36 (28.6) 16 (34
Risk factor
Diabetes mellitus 31 (24.6) 12 (26
Hypertension 67 (53.2) 28 (60
Hypercholesterolemia 46 (36.5) 15 (32
Current smoking 35 (27.8) 11 (23
Chronic kidney disease 4 (3.2) 0 (0)
History
Previous MI 70 (55.6) 28 (60
Previous CABG 1 (0.8) 0 (0)
Previous stroke 6 (4.8) 3 (6.
Concomitant medications
Statin 112 (88.9) 40 (87
CYP3A4 metabolized 89 (70.6) 28 (60
Beta-blocker 102 (81.0) 35 (76
Angiotensin antagonist 114 (90.5) 44 (95
Nitrate 91 (72.2) 31 (67
Calcium-channel blocker 30 (23.8) 9 (19
Proton pump inhibitor 1 (0.8) 1 (2.
LV ejection fraction 45% 18 (14.3) 7 (15
Hemoglobin, g/dl 13.7 2.6 13.3
Platelet count, 103/mm3 265 68 272
HbA1C, % 6.4 1.2 6.3
GFR (MDRD, ml/min/1.73 m2) 91.8 19.5 93.5
Total cholesterol, mg/dl 141.8 36.9 141.5
Multivessel disease 59 (46.8) 16 (34
Intervention method
Drug-eluting stent 122 (96.8) 46 (10
Bare-metal stent 0 (0) 0 (0)
Ballooning only 4 (3.2) 0 (0)
Multivessel intervention 35 (27.8) 9 (19
Stent diameter, mm 3.1 0.4 3.0
Stents per patient 1.6 0.8 1.6
Total stent length, mm 38.1 21.7 37.2
Values are mean SD or n (%) unless otherwise indicated.
CABG coronary artery bypass grafting; CYP the hepatic cytochr
left ventricular;MDRDmaximumdeflection ratiodetector;MImyoSTEMI ST-segment elevation myocardial infarction.igh-risk cohorts. Sixty-four patients (50.6%) were admit-
ed with acute myocardial infarction; 96.8% of the cohorts
ere treated with drug-eluting stents, and 59 patients
46.8%) had multivessel disease.
The genetic distributions for evaluated polymorphisms
ere similar to the published East Asian frequencies (30)
the CYP2C19 Variant Allele (*2 or *3)
1-Variant Carrier
(n  60)
2-Variant Carrier
(n  20) p Value
60.4 12.5 64.6 9.0 0.327
40 (66.7) 16 (80.0) 0.215
24.8 3.1 25.2 2.7 0.817
0.134
14 (23.3) 8 (40.0)
17 (28.3) 2 (10.0)
14 (23.3) 5 (25.0)
15 (25.0) 5 (25.0)
15 (25.0) 4 (20.0) 0.634
30 (50.0) 9 (45.0) 0.185
25 (41.7) 6 (30.0) 0.896
18 (30.0) 6 (30.0) 0.526
3 (5.0) 1 (5.0) 0.183
32 (53.3) 10 (50.0) 0.360
1 (1.7) 0 (0) 0.766
3 (5.0) 0 (0) 0.290
53 (88.3) 19 (95.0) 0.390
45 (75.0) 16 (80.0) 0.106
50 (83.3) 17 (85.0) 0.321
53 (88.3) 17 (85.0) 0.130
44 (73.3) 16 (80.0) 0.281
17 (28.3) 4 (20.0) 0.721
0 (0) 0 (0) 0.253
7 (11.7) 4 (20.0) 0.794
13.9 3.5 14.1 1.5 0.413
261 67 261 53 0.673
6.4 1.4 6.2 0.8 0.814
90.1 20.3 91.9 17.9 0.753
141.0 31.4 145.1 51.4 0.913
33 (55.0) 10 (50.0) 0.113
0.005
59 (95.0) 17 (85.0)
0 (0) 0 (0)
1 (1.7) 3 (15.0)
19 (31.7) 7 (35.0) 0.136
3.1 0.4 3.1 0.5 0.061
1.6 0.7 1.5 0.7 0.873
39.0 19.2 37.8 18.4 0.916
50; GFR glomerular filtration rate; HbA1C hemoglobin A1C; LV
nfarction;NSTEMInon–ST-segmentelevationmyocardial infarction;ge of
rrier
46)
9.4
.0)
2.7
.0)
.6)
.6)
.8)
.1)
.9)
.6)
.9)
.9)
5)
.0)
.9)
.1)
.7)
.4)
.6)
2)
.2)
1.3
75
1.3
19.4
36.9
.8)
0.0)
.6)
0.3
0.9
25.7
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736nd did not significantly deviate from Hardy-Weinberg
quilibrium (Table 2). As expected (24), carriage of the
YP2C19 variant allele (*2 or *3) was relatively high, 63.5%
f total (n  80): 60 carriers with 1 variant allele (47.6%)
nd 20 carriers with 2 variant alleles (15.9%). There were no
ifferences in platelet measures between carriers of the
YP2C19*2 versus *3 variant allele (data not shown). The
requency of RM was sufficient to perform the analyses for
he CYP3A5*3 and ABCB1 (Table 2).
In terms of the CYP2C19 mutant allele, baseline charac-
eristics were well matched between the groups except for a
igher prevalence of ballooning only in 2-variant carriers
Table 2. Distributions of Gene Polymorphisms
Gene Genotypes Predicted Function Distribution
CYP2C19 *1/*1 Normal 46 (36.5)
*1/*2 Decreased 45 (35.7)
*1/*3 Decreased 15 (11.9)
*2/*2 Decreased or absent 13 (10.3)
*2/*3 Decreased or absent 7 (5.6)
*3/*3 Decreased or absent 0 (0)
CYP3A5 *1/*1 Normal 8 (6.3)
*1/*3 Normal 35 (27.8)
*3/*3 Decreased or absent 83 (65.9)
ABCB1 CC Normal 56 (44.4)
CT Decreased 55 (43.7)
TT Decreased or absent 15 (11.9)
Values are n (%).
ABCB1 P-glycoprotein gene; other abbreviation as in Table 1.
Table 3. Platelet Reactivity and HPPR According to Gene Polymorphisms
CYP2C19
*1/*1
(n  46)
RMs*
(n  80)
Light transmittance aggregometry
5 mol/l ADP—PRmax (%) 30.3 12.6 40.7 16.8
p value 0.001
5 mol/l ADP—PRlate (%) 17.5 12.6 28.8 19.6
p value 0.001
20 mol/l ADP—PRmax (%) 40.5 15.8 54.2 16.2
p value 0.001
20 mol/l ADP—PRlate (%) 24.3 17.7 42.0 21.7
p value 0.001
VerifyNow P2Y12 assay
P2Y12 reaction unit 149.3 74.5 197.7 78.1
p value 0.001
% inhibition 55.7 20.4 37.6 22.4
p value 0.001
HPPR,† n (%) 4 (8.7) 23 (28.8)
p value 0.012
*RMs indicate reduced metabolizers (CYP2C19 1/2, 1/3, 2/2, 2/3 and 3/3). †HPPR indicates high postADP adenosine diphosphate; PRlate late platelet reactivity at 5 min; PRmaxmaximal platelet reactiTable 1). Baseline characteristics did not differ between
ormal metabolizers versus RMs of the CYP3A5*3 and
BCB1 c. 3435CT polymorphisms (data not shown).
DP-induced PR. According to predicted function deter-
ined by gene polymorphisms, ADP-induced PR on a
igh-MD clopidogrel is demonstrated in Table 3. Reduced
etabolizers of the CYP3A5*3 and ABCB1 c. 3435CT
enotypes did not show increased ADP-induced PR.
The PRmax values in carriers of the CYP2C19 mutant
llele were significantly higher than the values in noncarriers
Table 3). PRmax with 5 mol/l ADP stimulus was consis-
ently increased to 30.3 12.6%, 38.4 14.3%, and 47.8
1.9% in patients with 0, 1, and 2 CYP2C19 variant allele(s)
p  0.001), whereas it was 40.5  15.8%, 51.3  15.3%,
nd 62.8  16.3% with 20 mol/l ADP stimulus, respec-
ively (p  0.001) (Fig. 3).
The PRlate values were also significantly greater in carriers
f the CYP2C19 mutant allele than in noncarriers (Table 3).
Rlate after the addition of 5 mol/l ADP was 17.5 
2.6% in noncarriers, 26.1  16.0% in carriers of 1
YP2C19 mutant allele, and 37.2  26.6% in carriers of 2
YP2C19 mutant alleles (p  0.001), and 24.3  17.7%,
8.8  20.0%, and 51.8  25.0% after the addition of 20
mol/l ADP, respectively (p  0.001) (Fig. 4).
he VerifyNow P2Y12 assay. Compared with normal me-
abolizers on a high-MD clopidogrel, RMs of the
YP3A5*3 and ABCB1 genotypes did not differ in the
esults of the VerifyNow P2Y12 assay. Subjects without
he CYP2C19 mutant allele presented lower PRU and
CYP3A5 ABCB1
1/*1 *1/*3
(n  43)
*3/*3
(n  83)
CC
(n  56)
CTTT
(n  70)
35.3 15.1 37.8 16.8 38.4 16.0 35.8 16.4
0.424 0.382
21.7 16.5 26.3 18.9 25.7 17.9 23.9 18.5
0.183 0.597
48.2 17.5 49.6 17.3 51.3 17.8 47.4 16.9
0.670 0.211
33.1 21.8 36.8 22.1 37.8 22.2 33.8 21.9
0.370 0.313
184.0 80.0 178.0 80.3 187.2 87.2 174.3 73.9
0.693 0.370
45.2 21.4 43.7 24.4 42.1 23.7 45.9 23.1
0.734 0.364
10 (23.3) 17 (20.5) 13 (23.2) 14 (20.0)
0.819 0.669
ent platelet reactivity (5 mol/l ADP-induced maximal platelet reactivity 50%).*
-treatmvity; other abbreviations as in Tables 1 and 2.
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737igher % inhibition as compared with RMs (Table 3). PRU
onsecutively increased according to the number of the
YP2C19 variant alleles (149.3  74.5 in no-variant car-
iage vs. 182.5 72.9 in 1-variant carriage vs. 243.4 76.9
n 2-variant carriage, p  0.001) (Fig. 5A). The % inhibi-
ion was reduced 55.7  20.4%, 42.7  20.3%, and 22.0 
1.8% in subjects with 0, 1, and 2 CYP2C19 mutant allele(s)
p  0.001) (Fig. 5B).
ate and predictors of HPPR. Twenty-seven (21.4%) pa-
ients among all cohorts receiving a high-MD clopidogrel
et the criteria of HPPR. The CYP3A5*3 and ABCB1
.3435CT polymorphisms were not correlated with the
ncreased risk of HPPR (Table 3). Carriers of the CYP2C19
utant allele showed a greater risk of HPPR than did
oncarriers (28.8% vs. 8.7%, p  0.012). According to
arriage of the CYP2C19 variant, prevalence of HPPR was
.7% in noncarriers, 21.7% in carriers of 1 variant, and
0.0% in carriers of 2 variants (p  0.001) (Fig. 6).
To determine predictors of HPPR, a logistic regression
nalysis was performed to evaluate the impact of sex, age,
Figure 3. Maximal Platelet Reactivity After High
Maintenance-Dose Clopidogrel
Maximal platelet reactivity after high maintenance-dose clopidogrel. Num-
bers indicate numbers of the CYP2C19 variant alleles present. Bars indicate
standard deviations. ADP  adenosine diphosphate; ANOVA  analysis of
variance.ody mass index (BMI), gene polymorphisms, acute coro-ary syndrome at index PCI, current smoking, hyperten-
ion, diabetes mellitus, chronic kidney disease (CKD), left
entricular ejection fraction 45%, and use of the CYP3A4-
etabolized statin, beta-blocker, angiotensin antagonists,
itrate, calcium channel blocker, and proton pump inhibitor
Table 4). Carriage of the CYP2C19 variant allele (OR:
.525, 95% CI: 1.333 to 23.256, p  0.018) and diabetes
ellitus (OR: 4.539, 95% CI: 1.030 to 20.012, p  0.046)
ere significant predictors of HPPR. In addition, carriers of
CYP2C19 variant alleles showed a more significant asso-
iation with the risk of HPPR than did noncarriers (OR:
.428, 95% CI: 2.271 to 18.190, p  0.001).
iscussion
his ACCEL-DOUBLE study demonstrates that despite
se of a high-MD clopidogrel in high-risk patients
reated with PCI, carriers of the CYP2C19 variant allele
how higher platelet measures and an increased risk of
PPR than do noncarriers. Furthermore, this study
dentifies that the number of the CYP2C19 variant allele
arriage proportionally increases the risk of HPPR. These
Figure 4. Late Platelet Reactivity After High
Maintenance-Dose Clopidogrel
Late platelet reactivity after high maintenance-dose clopidogrel. Numbers
indicate numbers of the CYP2C19 variant alleles present. Bars indicate stan-
dard deviations. Abbreviations as in Figure 3.
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738esults suggest that carriage of the CYP2C19 polymorphism
s associated with the risk of HPPR in PCI-treated subjects
n a high-MD clopidogrel.
After the prodrug clopidogrel is orally administered,
onversion to the active metabolites requires absorption,
istribution, and metabolism. Response to clopidogrel is
elated with intestinal absorption, the CYP enzymatic activ-
ty (due to interacting drugs and genetic variants), P2Y12
eceptor density, and other factors, which account for the
ighly variable prevalence of inadequate response to clopi-
ogrel (31). Because recent large trials have demonstrated
hat the CYP2C19 loss-of-function allele is an exceedingly
mportant risk factor to predict enhanced on-treatment PR
nd adverse clinical outcomes (16,17,32), effective antiplate-
et therapy to override the impact of the CYP2C19 mutant
llele must be evaluated.
Although a high-MD clopidogrel achieves a greater
latelet inhibition than a standard-MD clopidogrel of 75
g/day (15,33), the efficacy of a high-MD clopidogrel in
igh-risk patients remains questionable. In the OPTIMUS
Optimizing Antiplatelet Therapy in Diabetes Mellitus)
tudy, high-MD clopidogrel, when compared with
tandard-MD clopidogrel, enhanced antiplatelet effects in
Figure 6. Rate of HPPR After High Maintenance-Dose Clopidogrel
Rate of HPPR after high maintenance-dose clopidogrel. Numbers indicate
numbers of the CYP2C19 variant alleles present. HPPR  high post-treatment
platelet reactivity (5 mol/l ADP-induced maximal platelet reactivity 50%);Figure 5. P2Y12 Reaction Unit and % Inhibition After High
Maintenance-Dose Clopidogrel
P2Y12 reaction unit (A) and percentage of inhibition (B) after high
maintenance-dose clopidogrel. Numbers indicate numbers of the
CYP2C19 variant alleles present. Bars indicate standard deviations.other abbreviation as in Figure 3.
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739ype 2 diabetic patients, but a suboptimal response to
lopidogrel (20 mol/l ADP-induced PRmax 50%) per-
isted in 60% of patients on the 150-mg regimen. Because
high-MD clopidogrel also may inhibit ADP-stimulated
latelet aggregation depending on the CYP2C19 genotype,
here was a need to determine if carriers of the CYP2C19
ariant may benefit from increased dose of clopidogrel (32).
t is noteworthy that in a small-size study (n  6),
ncreasing the dose of clopidogrel could not override the
ffect of the CYP2C19 variant in patients with stent throm-
osis (18). Furthermore, in a recent study including Korean
atients, Park et al. (34) demonstrated that antiplatelet
esponse to clopidogrel decreased more in CKD patients
han in controls, and a double dose of clopidogrel in CKD
atients could not sufficiently inhibit increased PR. Al-
hough this result may reflect platelet dysfunction in CKD
atients, it also may imply the limited benefit of high-MD
lopidogrel in patients with high prevalence of the
YP2C19 variant (about 60% in East Asians) (24). In
tudies of the PREDICT (Residual Platelet Aggregation
fter Deployment of Intracoronary Stent) score (29) and
onello-Palot et al. (35), prediction of HPPR after a
00-mg loading dose of clopidogrel was significantly influ-
nced by the CYP2C19 polymorphism and clinical risk
actors (high BMI, ACS, age 65 years, diabetes mellitus,
KD, and reduced left ventricular function). Thus, CKD
atients with the CYP2C19 variant may not achieve ade-
uate platelet inhibition despite use of high-MD clopi-
Table 4. Predictors for HPPR by Univariate and Multivariate Logistic Regre
Univariate A
Variables OR (95% CI)
Carriage of CYP2C19 variant 4.237 (1.362–13.158)
CYP3A53/3 carriers 0.850 (0.351–2.061)
Carriage of ABCB1 variant 0.827 (0.352–1.941)
Female sex 1.931 (0.806–4.627)
Age (per 10-yr increment) 1.267 (0.847–1.901)
Body mass index (per 1 increment) 1.014 (0.874–1.176)
Acute coronary syndrome at index PCI 2.040 (0.850–4.896)
Current smoking 0.523 (0.181–1.511)
Hypertension 1.070 (0.456–2.508)
Diabetes mellitus 3.155 (0.879–11.318)
Chronic kidney disease 1.230 (0.123–12.346)
LV ejection fraction 45% 2.410 (0.518–11.200)
CYP3A4-metabolized statin 1.268 (0.509–3.156)
Beta-blocker 3.571 (0.784–16.393)
Angiotensin blocker 0.800 (0.201–3.185)
Calcium-channel blocker 1.156 (0.434–3.077)
Nitrate 0.690 (0.252–1.885)
Proton pump inhibitor —
OR odds ratio; PCI percutaneous coronary intervention; other abbreviations as in Tables 1 to 3ogrel. Moreover, the present study provides laboratory avidence that high-risk carriers of the CYP2C19 variant still
ave a risk for suboptimal platelet inhibition despite use of
high-MD clopidogrel (21.7% in heterozygotes and 50.0%
n homozygotes). These results provide a rationale for
urther studies to assess whether high-MD clopidogrel, as
ompared with noncarriers of the CYP2C19 variant, pro-
ides long-term clinical benefits in carriers.
Subjects with the CYP2C19 polymorphism may benefit
ore from antiplatelet regimens that do not include clopi-
ogrel, such as use of third-generation thienopyridines
14,15,32), or the addition of a third antiplatelet agent, such
s cilostazol (19,20). Third-generation thienopyridines pre-
ominantly do not use the CYP2C19 pathway for activation,
nd therefore can inhibit platelet aggregation sufficiently
egardless of CYP2C19 polymorphism. Cilostazol is mainly
onverted into active metabolites by the CYP3A system (36),
hich implies less of an impact of the CYP2C19 mutant
llele on the additive platelet inhibition by cilostazol.
Because the CYP2C19 genotype may be useful to deter-
ine antiplatelet regimen and dose (32), this concept may
e more important among East Asians with a higher
revalence of the CYP2C19 variant than in Caucasians.
owever, results of the CHARISMA (Clopidogrel for
igh Atherothrombotic Risk and Ischemic Stabilization,
anagement, and Avoidance) substudy (37) undermined
his reasoning. Compared with other ethnic groups, Asian
ohorts showed the lowest incidence of cardiovascular mor-
ality and a higher risk of moderate bleeding (37). The risk
Models
s Multivariate Analysis
p Value OR (95% CI) p Value
0.013 5.525 (1.333–23.256) 0.018
0.719 0.609 (0.575–4.914) 0.369
0.662 0.691 (0.243–1.961) 0.487
0.140 2.370 (0.707–7.937) 0.162
0.248 1.070 (0.599–1.912) 0.819
0.853 1.075 (0.887–1.304) 0.457
0.111 2.828 (0.589–13.579) 0.194
0.231 0.691 (0.113–4.237) 0.690
0.877 1.073 (0.346–3.333) 0.902
0.078 4.539 (1.030–20.012) 0.046
0.860 1.410 (0.102–19.498) 0.798
0.262 2.598 (0.5442–15.275) 0.291
0.610 1.624 (0.505–5.223) 0.416
0.100 4.608 (0.780–27.027) 0.092
0.752 0.807 (0.145–4.498) 0.806
0.771 1.785 (0.456–6.996) 0.405
0.469 0.528 (0.166–1.676) 0.279
1.000 — 1.000ssion
nalysissociated the CYP2C19 variant can differ according to
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740enetic background or environmental exposures (32). Be-
ause East Asians show a lower response to clopidogrel with
esser rates of clinical events than Caucasians do, the cutoff
oints of HPPR suggested by platelet function assays can
iffer from those based on the Caucasian population.
herefore, the cutoff of HPPR and the effect of intensified
ntiplatelet regimens according to ethnicity must be evalu-
ted to balance the efficacy and safety of intensified anti-
latelet therapy. In addition, we should not neglect the
omplex interaction between specific environmental factors
nd gene expression in the context of the thrombotic
rocess. Although some medications and environmental
actors cause decreased response to clopidogrel in terms of
ene expression, these factors also can differentially affect
ene expression related to atherothrombosis. Consequently,
ntricate interactions of environmental factors and gene
xpression may make it difficult to identify direct cause-
ffect networks.
tudy limitations. First, the present study is an observational
tudy including a heterogeneous set of subjects with a small
ample size. Sample size and frequency of HPPR are
nsufficient to yield solid predictors in multivariate analysis,
s indicated by the wide CIs. Second, the present study
howed laboratory data only without clinical outcomes.
hird, the impact of the CYP2C19 genotype on clopidogrel
esponse can change with time. The present study may not
alidate the optimal duration of intensified antiplatelet
herapy in high-risk patients. Fourth, proton pump inhibi-
ors can affect the enzymatic activity of the CYP2C19
athway, especially in carriers of the CYP2C19 variant.
owever, because few patients were on proton pump
nhibitors due to a physician’s preference in the present
tudy, we could not ascertain this hypothesis appropriately.
ifth, Bonello-Palot et al. (35) showed that high BMI could
e related with HPPR after a 600-mg loading dose of
lopidogrel. Because our patients’ mean BMI is relatively
ower than that in Bonello-Palot et al. (35) (24.8  2.7
g/m2 vs. 27.1  4.1 kg/m2), the impact of BMI on HPPR
an be underestimated in the present study. Finally, we
erformed DNA genotyping for some chosen gene poly-
orphisms, and we could not absolutely exclude the impact
f other gene polymorphisms.
onclusions
mong PCI-treated patients receiving a high-MD clopi-
ogrel of 150 mg/day, carriage of the CYP2C19 variant
llele is related to increased PR and predicts risk of HPPR.
t remains to be evaluated whether carriers of the CYP2C19
ariant allele treated with a high-MD clopidogrel may show
oorer cardiovascular outcomes than noncarriers would.cknowledgment
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